Literature DB >> 18165516

Year-to-year variation in the age-specific incidence of clinical malaria in two potential vaccine testing sites in Mali with different levels of malaria transmission intensity.

Alassane Dicko1, Issaka Sagara, David Diemert, Moussa Sogoba, Mohamed B Niambele, Adama Dao, Guimogo Dolo, Daniel Yalcouye, Dapa A Diallo, Allan Saul, Louis H Miller, Yeya T Toure, Amy D Klion, Ogobara K Doumbo.   

Abstract

To explore the feasibility of field sites for malaria vaccine trials, we conducted a prospective study of clinical malaria incidence during two consecutive transmission seasons in children and young adults living in two areas of Mali with different entomologic inoculation rates (EIRs). Approximately 200 subjects (3 months to 2 years of age) were enrolled per site and followed weekly. Malaria smears were performed monthly in all participants and when symptoms or signs of malaria were present. In Sotuba (annual EIR < 15 infective bites per person), the incidence of clinical malaria was comparable across all age groups but varied significantly between the 2 years. In contrast, in Donéguébougou (annual EIR > 100 infective bites per person), incidence rates decreased significantly with increasing age but remained stable between years. Our results suggest that, although the age distribution of clinical malaria depends on transmission intensity, the total burden of disease may be similar or higher in settings of low transmission.

Entities:  

Mesh:

Year:  2007        PMID: 18165516

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  25 in total

1.  Promoting good clinical laboratory practices and laboratory accreditation to support clinical trials in sub-Saharan Africa.

Authors:  Merepen A Guindo; Joseph P Shott; Renion Saye; Moussa L Diakité; Sintry Sanogo; Moussa B Dembele; Sekouba Keita; Mary C Nagel; Ruth D Ellis; Joan A Aebig; Dapa A Diallo; Ogobara K Doumbo
Journal:  Am J Trop Med Hyg       Date:  2012-04       Impact factor: 2.345

2.  Comparison of biological activity of human anti-apical membrane antigen-1 antibodies induced by natural infection and vaccination.

Authors:  Kazutoyo Miura; Hong Zhou; Samuel E Moretz; Ababacar Diouf; Mahamadou A Thera; Amagana Dolo; Ogobara Doumbo; Elissa Malkin; David Diemert; Louis H Miller; Gregory E D Mullen; Carole A Long
Journal:  J Immunol       Date:  2008-12-15       Impact factor: 5.422

3.  Development of clinical immunity to malaria in highland areas of low and unstable transmission.

Authors:  Melissa A Rolfes; Matthew McCarra; Ng'wena G Magak; Kacey C Ernst; Arlene E Dent; Kim A Lindblade; Chandy C John
Journal:  Am J Trop Med Hyg       Date:  2012-09-17       Impact factor: 2.345

4.  Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial.

Authors:  Mahamadou S Sissoko; Sara A Healy; Abdoulaye Katile; Freda Omaswa; Irfan Zaidi; Erin E Gabriel; Bourama Kamate; Yacouba Samake; Merepen A Guindo; Amagana Dolo; Amadou Niangaly; Karamoko Niaré; Amatigue Zeguime; Kourane Sissoko; Hama Diallo; Ismaila Thera; Kelly Ding; Michael P Fay; Elise M O'Connell; Thomas B Nutman; Sharon Wong-Madden; Tooba Murshedkar; Adam J Ruben; Minglin Li; Yonas Abebe; Anita Manoj; Anusha Gunasekera; Sumana Chakravarty; B Kim Lee Sim; Peter F Billingsley; Eric R James; Michael Walther; Thomas L Richie; Stephen L Hoffman; Ogobara Doumbo; Patrick E Duffy
Journal:  Lancet Infect Dis       Date:  2017-02-16       Impact factor: 25.071

5.  Multiple Phenotypic and Genotypic Artemisinin Sensitivity Evaluation of Malian Plasmodium falciparum Isolates.

Authors:  Karamoko Niaré; Lucie Paloque; Sandie Ménard; Pety Tor; Arba P Ramadani; Jean-Michel Augereau; Antoine Dara; Antoine Berry; Françoise Benoit-Vical; Ogobara K Doumbo
Journal:  Am J Trop Med Hyg       Date:  2018-02-08       Impact factor: 2.345

6.  Increase in EPI vaccines coverage after implementation of intermittent preventive treatment of malaria in infant with Sulfadoxine -pyrimethamine in the district of Kolokani, Mali: results from a cluster randomized control trial.

Authors:  Alassane Dicko; Sidy O Toure; Mariam Traore; Issaka Sagara; Ousmane B Toure; Mahamadou S Sissoko; Alpha T Diallo; Christophe Rogier; Roger Salomon; Alexandra de Sousa; Ogobara K Doumbo
Journal:  BMC Public Health       Date:  2011-07-18       Impact factor: 3.295

Review 7.  Age-patterns of malaria vary with severity, transmission intensity and seasonality in sub-Saharan Africa: a systematic review and pooled analysis.

Authors:  Ilona Carneiro; Arantxa Roca-Feltrer; Jamie T Griffin; Lucy Smith; Marcel Tanner; Joanna Armstrong Schellenberg; Brian Greenwood; David Schellenberg
Journal:  PLoS One       Date:  2010-02-01       Impact factor: 3.240

8.  Spatial Patterns of Plasmodium falciparum Clinical Incidence, Asymptomatic Parasite Carriage and Anopheles Density in Two Villages in Mali.

Authors:  Mahamadou S Sissoko; Lotus L van den Hoogen; Yacouba Samake; Amadou Tapily; Adama Z Diarra; Maimouna Coulibaly; Madama Bouare; Jean Gaudart; Philip Knight; Robert W Sauerwein; Willem Takken; Teun Bousema; Ogobara K Doumbo
Journal:  Am J Trop Med Hyg       Date:  2015-08-31       Impact factor: 2.345

9.  A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults.

Authors:  Issaka Sagara; Ruth D Ellis; Alassane Dicko; Mohamed B Niambele; Beh Kamate; Ousmane Guindo; Mahamadou S Sissoko; Michael P Fay; Merepen A Guindo; Ousmane Kante; Renion Saye; Kazutoyo Miura; Carole Long; Gregory E D Mullen; Mark Pierce; Laura B Martin; Kelly Rausch; Amagana Dolo; Dapa A Diallo; Louis H Miller; Ogobara K Doumbo
Journal:  Vaccine       Date:  2009-10-27       Impact factor: 3.641

10.  A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali.

Authors:  Issaka Sagara; Alassane Dicko; Ruth D Ellis; Michael P Fay; Sory I Diawara; Mahamadoun H Assadou; Mahamadou S Sissoko; Mamady Kone; Abdoulbaki I Diallo; Renion Saye; Merepen A Guindo; Ousmane Kante; Mohamed B Niambele; Kazutoyo Miura; Gregory E D Mullen; Mark Pierce; Laura B Martin; Amagana Dolo; Dapa A Diallo; Ogobara K Doumbo; Louis H Miller; Allan Saul
Journal:  Vaccine       Date:  2009-03-25       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.